Innovation for Your Health

All news from Hamburg
and Schleswig-Holstein


Evotec and Celmatix enter into strategic collaboration

Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions...


Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. (“Aeovian”)....


Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify...


Evotec and Takeda enter collaboration

Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Under the collaboration, the parties aim to establish at least five drug...


Eppendorf AG: Positive first half-year 2019

The globally active Eppendorf Group charted a strong first half-year in 2019 with a significant surge in Group sales to €378.5 million (prior year: €335.6 million). This positive development...


Evotec expands its iPSC discovery platform

Evotec SE announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry....


New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents: Gram-Negative Antibacterials NOW (“GNA NOW”). The new GNA NOW project, led by...


Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"

Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets...


CORNET issues Calls for Proposals

The 28th CORNET Call for Proposals is now OPEN! Submission is possible until 25 September 2019, 12 p.m. (CET) via the Submission Tool. Twice a year, CORNET issues Calls for Proposals for...


Evotec create a new bridge partnership in digital health

Evotec SE announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford...

© Copyright Life Science Nord e.V.

All rights reserved. Especially reprint, incorporation in online services, internet and amplification using data vehicles like CD-Rom, DVD-ROM etc. even in extracts require written permission by Life Science Nord e.V. Life Science NOrd e.V. is not responsible for content of external links and and foreign contents.

In case you would like to use our newsletter via email as a free-of-charge and effective PR tool, please send us your company news that we eill publish in the following issue. Profit from this communication platform, make new contacts and take care of existing ones.


Simone Hauck
PR & Communications Manager

P +49.40.471 96-423


  • Desitin

Content loading failure